The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women | Zendy

Kristof Chwalisż | Zendy; W. Elger | Zendy; Therese Stickler | Zendy; Cynthia MattiaGoldberg | Zendy; Lois Larsen | Zendy

Open Access

The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women

Author(s) -

Kristof Chwalisż,

W. Elger,

Therese Stickler,

Cynthia MattiaGoldberg,

Lois Larsen

Publication year - 2005

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deh738

Subject(s) - luteal phase , endocrinology , follicular phase , medicine , prolactin , menstrual cycle , estrogen , progesterone receptor , levonorgestrel , placebo , endometrium , menstruation , agonist , hormone , receptor , estrogen receptor , population , breast cancer , alternative medicine , environmental health , pathology , cancer , family planning , research methodology

Asoprisnil (J867) is a novel selective progesterone receptor modulator (SPRM) that exhibits partial agonist and antagonist activities and tissue selective effects. This double-blind, dose-escalation study was conducted to evaluate the effects of asoprisnil in 60 regularly cycling premenopausal women.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research